Downtrend on the daily chart: below its 50-day average · SuperTrend down since Jul 22 · below the Ichimoku cloud · RSI 48 · MACD above its signal
| 15.29 | 52-week high | +69.14% |
| 12.32 | Previous month high | +36.28% |
| 9.71 | R3 (classic) | +7.37% |
| 9.45 | R2 (classic) | +4.57% |
| 9.25 | R1 (classic) | +2.29% |
| 9.20 | Previous day high | +1.77% |
| 9.04 | Price now | |
| 8.99 | Pivot | −0.52% |
| 8.86 | Previous week high | −1.99% |
| 8.79 | S1 (classic) | −2.80% |
| 8.74 | Previous day low | −3.32% |
| 8.53 | S2 (classic) | −5.60% |
| 8.45 | Previous month low | −6.53% |
| 8.33 | S3 (classic) | −7.89% |
| 8.04 | Previous week low | −11.06% |
| 8.03 | 52-week low | −11.17% |
None of the 29 investors followed here reported a position in MOBI in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MOBI trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
TimeframesUp on the hourly, mixed on the daily.
over a rising 21 EMA, 21 over 50
bouncing over the 21 EMA
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 10, 2026 | Leavitt Chase C.Officer | Purchase at price 10.30 per share. | 2K | $20.60K |
| Sep 1, 2026 | Rawat Prashant BChief Operating Officer | Conversion of Exercise of derivative security at price 3.38 per share. | 15K | $50.70K |
| Aug 17, 2026 | Tansey Casey MDirector | Purchase at price 12.07 per share. | 16.4K | $198.52K |
| Aug 16, 2026 | Tansey Casey MDirector | Purchase at price 11.51 - 12.53 per share. | 68.6K | $797.17K |
| Jun 9, 2026 | Rawat Prashant BChief Operating Officer | Conversion of Exercise of derivative security at price 3.38 per share. | 15K | $50.70K |
| Jun 8, 2026 | Curnes Nelson BunkerChief Financial Officer | Purchase at price 12.79 per share. | 5K | $63.97K |
| May 10, 2026 | Lucchese Cynthia LDirector | Purchase at price 12.00 per share. | 125K | $1.50M |
| May 10, 2026 | Tansey Casey MDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 12.00 per share. | 66.7K | $799.99K |
| May 10, 2026 | Tansey Casey MDirector and Beneficial Owner of more than 10% of a Class of Security | — | 3.79M | — |
| May 10, 2026 | Mead Dana G JrDirector | Purchase at price 12.00 per share. | 7K | $84.00K |
| May 10, 2026 | Leavitt Chase C.General Counsel | Purchase at price 12.00 per share. | 3K | $36.00K |
| May 10, 2026 | Green Park & Golf Ventures Ii, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 12.00 per share. | 81K | $972.00K |
| May 10, 2026 | Green Park & Golf Ventures Ii, L.L.C.Beneficial Owner of more than 10% of a Class of Security | — | 71.2K | — |
| May 10, 2026 | Green Park & Golf Ventures Ii, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Sale at price 12.00 per share. | 6.7K | $80.77K |
| May 10, 2026 | Green Park & Golf Ventures Ii, L.L.C.Beneficial Owner of more than 10% of a Class of Security | — | 1.22M | — |
| May 10, 2026 | Green Park & Golf Ventures Ii, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 12.00 per share. | 33.3K | $400.00K |
| May 10, 2026 | Green Park & Golf Ventures Ii, L.L.C.Beneficial Owner of more than 10% of a Class of Security | — | 967.6K | — |
| May 10, 2026 | Green Park & Golf Ventures Ii, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 12.00 per share. | 60.5K | $726.44K |
| May 10, 2026 | Green Park & Golf Ventures Ii, L.L.C.Beneficial Owner of more than 10% of a Class of Security | — | 386.7K | — |
| May 10, 2026 | Green Park & Golf Ventures Ii, L.L.C.Beneficial Owner of more than 10% of a Class of Security | — | 874.4K | — |
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.
Buy / hold / sell counts